8-K filed October 14, 2021, 7:59 PM ET ticker TENX CIK 0000034956

leadership confidence high sentiment neutral materiality 0.60

Tenax Therapeutics President/CFO Michael Jebsen to depart Oct 29; CEO Giordano becomes President; interim CFO appointed

TENAX THERAPEUTICS, INC.

Michael B. Jebsen (President & CFO) to depart Oct 29, 2021; receives 12 months base salary severance + prorated bonus.
CEO Christopher T. Giordano will assume additional role of President effective upon separation.
Eliot M. Lurier appointed Interim CFO via Danforth Advisors; Danforth receives $400/hour for his services.
Jebsen to provide advisory services through April 2022 at $275/hour under a 6-month consulting agreement.
Board initiates search for a permanent Chief Financial Officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael B. Jebsen

President

TENX · TENAX THERAPEUTICS, INC.

Effective: 2021-10-29
Successor: Christopher T. Giordano
Filed: October 14, 2021, 7:59 PM ET

Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021

Role change

Christopher T. Giordano

President

TENX · TENAX THERAPEUTICS, INC.

Effective: 2021-10-29
Filed: October 14, 2021, 7:59 PM ET

the Company’s current Chief Executive Officer and principal executive officer, Christopher T. Giordano, will assume the additional position of President of the Company.

Departed

Michael B. Jebsen

Chief Financial Officer

TENX · TENAX THERAPEUTICS, INC.

Effective: 2021-10-29
Successor: Eliot M. Lurier
Filed: October 14, 2021, 7:59 PM ET

Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021

Appointed (interim)

Eliot M. Lurier

Interim Chief Financial Officer

TENX · TENAX THERAPEUTICS, INC.

Effective: 2021-10-29
Filed: October 14, 2021, 7:59 PM ET

the Company has entered into a consulting agreement with Danforth Advisors, LLC (“Danforth”), dated October 14, 2021, providing for the engagement of Eliot M. Lurier, a consultant with Danforth, as Interim Chief Financial Officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael B. Jebsen departed as President at TENAX THERAPEUTICS, INC..

Action: separated
Role: President

Exact text from the filing

Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher T. Giordano changed role as President at TENAX THERAPEUTICS, INC..

Action: assumed additional role of
Role: President

Exact text from the filing

the Company’s current Chief Executive Officer and principal executive officer, Christopher T. Giordano, will assume the additional position of President of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael B. Jebsen departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..

Action: separated
Role: Chief Financial Officer

Exact text from the filing

Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eliot M. Lurier was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

the Company has entered into a consulting agreement with Danforth Advisors, LLC (“Danforth”), dated October 14, 2021, providing for the engagement of Eliot M. Lurier, a consultant with Danforth, as Interim Chief Financial Officer of the Company

View on SEC.gov

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-21-011095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.